0L49 Stock Chart & Stats
$5.48
$0.80(21.84%)
At close: 4:00 PM EDT
$5.48
$0.80(21.84%)
Day’s Range― - ―
52-Week Range$3.59 - $9.20
Previous CloseN/A
Volume11.29K
Average Volume (3M)7.15K
Market Cap
$46.37M
Enterprise Value-$4.09
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 11, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume19,225
30 Day Avg. Volume7,153
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.00Price Target Upside483.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.47
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Non-dilutive BARDA Pipeline FundingBARDA's cost-share contract can materially extend development funding without relying solely on equity issuance, while supporting SCY-247 through Phase 2 and potential regulatory submissions. That improves pipeline execution capacity and makes the stated runway more durable.
Conservative Balance-sheet LeverageDebt-to-equity of about 0.03 indicates conservative leverage and gives SCYNEXIS more balance-sheet flexibility while it advances clinical programs. Compared with the earlier highly leveraged period, the stronger capital structure can reduce pressure on near-term funding decisions.
Experienced Biopharma GovernanceAdding an experienced biopharma director with drug-development and company-building experience strengthens governance as SCYNEXIS advances rare-disease and antifungal programs. His background is relevant to strategic execution, clinical development, and future corporate transactions.
Bears Say
Persistent Unprofitability And Revenue ContractionTTM net margin near -54%, with deeply negative EBIT and EBITDA margins, shows that the current operating model is not yet profitable. The sharp revenue decline means scale and commercialization have not translated into durable earnings, leaving profitability dependent on future execution.
Ongoing Operating Cash BurnNegative TTM operating and free cash flow of about $13.3 million demonstrates continued cash consumption despite improvement from 2024. Because operations are not self-funding, sustained clinical investment will keep financial flexibility tied to available cash and external funding.
Negative Returns On EquityNegative ROE in the TTM and recent years indicates the company is not currently generating returns on its equity base. If losses persist, they can continue to erode equity and constrain the ability to reinvest in pipeline programs without additional financing.
SCYNEXIS News
0L49 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest share price was $3.59 and its highest was $9.20 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $46.37M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 41 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.72.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -9.528%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in GB:0L49
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (483.94% Upside)
$32.00 (483.94% Upside)
Blogger Sentiment
Bullish
GB:0L49 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
0L49 Stock 12 Month Forecast
Average Price Target
$32.00
▲(483.94% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―